Baricitinib

Patients with alopecia areata had greater improvements with baricitinib treatment compared placebo, according to an interim analysis presented at Maui Derm for Dermatologists.

For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years.

We end the year with Leonard Calabrese, DO, giving us a summary of what we’ve learned about COVID-19 from the perspective of a rheumatologist.

On the evening of Nov. 19, the FDA issued an emergency use authorization for the rheumatoid arthritis drug baricitinib in combination with remdesivir for patients hospitalized with suspected or confirmed COVID-19.

The FDA issued an emergency use authorization for baricitinib in combination with remdesivir for patients hospitalized with suspected or confirmed COVID-19, according to a press release.

A long-term safety study of baricitinib for rheumatoid arthritis, with more than 13,000 patient-years of exposure, found no increase in safety issues for up to 8.4 years, according to a speaker at ACR Convergence.

Patients with COVID-19 who were treated with baricitinib and remdesivir had a lower median time to hospital discharge and lower mortality rates than patients treated with remdesivir alone, Eli Lilly & Co. and Incyte announced in a press release.

The European Medicines Agency has recommended an extension to baricitinib’s indications to include the treatment of moderate to severe atopic dermatitis, according to a press release.

Eli Lilly & Co. announced that its JAK inhibitor baricitinib, when combined with remdesivir, reduced the time to recovery in patients with COVID-19 compared with remdesivir alone.

Baricitinib was linked to increased rates of overall infections, including herpes zoster, among patients with rheumatoid arthritis but did not impact incidence of serious infections, researchers noted in the Annals of the Rheumatic Diseases.